Evogene Reports H1 2026 Loss, Fully Utilizes ATM, and Faces Nasdaq Deadline and Dissident Tender Offer
EVGN is trading near its 52-week low of $0.352 (11% above the low) on light trading volume (0.2× avg).
Summary
Evogene reported a $7.7M H1 2026 loss, fully utilized its $3.3M ATM, and disclosed it missed the Nasdaq $1.00 bid price deadline, requesting a 180-day extension with a reverse split likely. Dissident shareholders also noticed a special tender offer.
Key Events · Earnings and Guidance · EVGN
-
H1 2026 Loss of $7.7M
Revenues fell to $0.7M from $2.9M in H1 2025, driven by the loss of Casterra seed sales. Operating loss was $5.4M, with total loss of $7.7M.
-
ATM Fully Utilized
The company sold 4,515,898 additional shares in July-August 2026 at an average of $0.542, raising ~$2.45M and fully exhausting the $3.3M ATM program. Total shares outstanding reached 18,052,405 as of August 31, 2026.
-
Nasdaq Compliance Deadline Missed
The September 28, 2026 deadline to regain the $1.00 minimum bid price passed without compliance. Evogene requested a 180-day extension on September 9, 2026 and intends to effect a reverse split if necessary.
-
Dissident Tender Offer Notice
On September 8, 2026, dissident shareholders L.I.A. Pure Capital and Invest Pro Shukai Hon served notice of intent to launch a special tender offer under Section 328 of Israeli Companies Law.
Analysis · EVGN · Industrial Applications And Services
Evogene's H1 2026 results show a $7.7M loss with revenues collapsing to $0.7M from $2.9M a year earlier, while the company fully exhausted its upsized $3.3M ATM program by selling 4.5M additional shares at an average of $0.542. The filing also reveals the Nasdaq minimum bid price deadline of September 28, 2026 has passed without regaining compliance, and the company has requested a 180-day extension with a reverse split as the likely remedy. Against this backdrop, dissident shareholders served notice on September 8, 2026 of their intent to launch a special tender offer, escalating the ongoing proxy battle. The combination of severe cash burn, full ATM utilization, delisting risk, and activist pressure makes this a critical update for investors.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 28.8% of the 1461 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVGN was trading at $0.39 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6M. The 52-week trading range was $0.35 to $1.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.